Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771044 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL27608732 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7615152 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL8609821 | 0.79 | TAS1R3 (0.45) | FOLH1MME | |
| SCHEMBL7411479 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL3674350 | 0.77 | — | — | |
| SCHEMBL30211920 | 0.77 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL3185989 | 0.76 | PPID (0.43) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL23883376 | 0.75 | ALDH1A1 (0.52) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL29233150 | 0.75 | ALDH1A1 (0.52) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | claimed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | claimed |
| EP-2450374-B1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | claimed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | claimed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | claimed |
| US-20190202883-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-04 | — | — | US | disclosed |
| US-10087229-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160052988-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9200051-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2450374-B1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-20140357552-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052988-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, VIP | ALDH1A1 4678/4885MEN1 192/4885LMNA 3090/4885 |
| US-20190202883-A1 | PEPTIDE COMPOUND | IAPP, VIP, GLP1R | ALDH1A1 3882/4885MEN1 112/4885LMNA 1271/4885 |
| US-20140357552-A1 | PEPTIDE COMPOUND | GLP1R, GIPR, VIP | ALDH1A1 4456/4885MEN1 62/4885LMNA 2310/4885 |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | ALDH1A1 3781/4885MEN1 949/4885LMNA 3526/4885 |
| US-10087229-B2 | Peptide compound | GLP1R, GIPR, VIP | ALDH1A1 4351/4885MEN1 48/4885LMNA 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.